ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

eClinical Solutions Announces Integrated Data Review Plan (IDRP) Capabilities Within elluminate Platform

Company becomes the first to centralize digital data review activities within a single platform as the industry focuses on clinical trial efficiency

eClinical Solutions LLC, a global provider of digital clinical software and services, today introduced a digitized Integrated Data Review Plan (IDRP), which further enhances the elluminate Clinical Data Cloud® as a comprehensive, end-to-end solution for data ingestion, cleaning, review, visualization, and analysis. By incorporating an IDRP, clinical trial leaders can streamline workflows, enhance collaboration, and improve efficiency, no longer needing to switch between multiple tools or utilize outdated external review plans in spreadsheets. The company is the first in the industry to centralize all review activities including a digital IDRP within a clinical data platform, further enabling sponsors to accelerate digital strategies throughout the data lifecycle.

In proprietary data from eClinical Solutions’ most recent Industry Outlook Survey, life sciences organizations reported that ensuring data quality and providing real-time access to data are the top two challenges they are addressing in 2025. While quality data will always be the priority, the emphasis on real-time data access points to the industry need for infrastructure that can streamline digital data flows for rapid decision-making and enhance collaboration across stakeholders.

Utilizing the IDRP within elluminate Data Central, users can now build, manage, track, and execute review plans, giving reviewers insight on what needs attention and access to supporting materials with a single click. The platform links review objectives to review materials such as listings, visualizations, and analytics dashboards, automatically tracks progress and completion for audit readiness, and highlights objectives tied to critical data. With cycle time as the new currency in drug development, these capabilities streamline review execution and oversight to reduce cycle time and manual burden, while strengthening compliance and inspection readiness to deliver operational efficiency at scale.

“From our data, we know only 26% of clinical development professionals are very satisfied with the speed at which their organizations are innovating data strategies and processes,” said Raj Indupuri, CEO and co-founder of eClinical Solutions. “To conduct modern trials, experts need a successful tech stack to transform data delivery, which is why the inclusion of the IDRP for elluminate was a natural next evolution. The digital IDRP provides industry leaders with a more efficient way to execute their digital data review strategies so they can meaningfully accelerate cycle times and boost R&D productivity.”

In addition to the introduction of IDRP, further elluminate platform updates include:

  • RACT & RBQM Enhancements: The elluminate risk management suite, including RBQM and the RACT workflow and assessment process, have been enhanced for increased adaptability to diverse industry practices and a connected experience aligned with ICH E6 (R3).
  • RACT AI-Powered Risk Statement Generation: A new AI-powered Risk Statement generation tool has been added to RACT to help users generate risk statements more accurately and efficiently.
  • New Sheet in Sample Management Analytics: A new “Missing or Delayed Samples” sheet within Sample Management Analytics highlights samples that exceed user-defined thresholds for Days At Site, In Transit, or At Lab – enabling users to quickly identify potential sample delays or misplacements.
  • New Integrations: Easily bring in data from the Clario eCOA Clinical Trial platform and SAS Life Science Analytics Framework (LSAF) using new API connections.

To learn more about elluminate and the recent product enhancements, visit: https://www.eclinicalsol.com/platform/.

About eClinical Solutions

eClinical Solutions’ industry-leading data & analytics platform, elluminate®, and biometrics services experts help biopharma researchers at large, mid-size, and emerging life sciences organizations manage trial complexity in less time and with fewer resources. Clients get accurate and timely data insights for better decision-making – enabling them to reduce cycle times, improve productivity, easily scale, and develop tomorrow’s breakthroughs with today’s resources. eClinical is a privately-held, purpose-driven company with a global workforce and winner of two 2025 Top Workplaces Culture Excellence Awards, the 2024 Top Workplaces USA Award, and Great Place To Work® India Certification™. Learn more at www.eclinicalsol.com and follow eClinical Solutions on LinkedIn.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  210.00
+2.08 (1.00%)
AAPL  264.18
-8.77 (-3.21%)
AMD  200.21
-3.47 (-1.70%)
BAC  49.83
-2.47 (-4.72%)
GOOG  311.43
+4.28 (1.39%)
META  648.18
-8.83 (-1.34%)
MSFT  392.74
-8.98 (-2.24%)
NVDA  177.10
-7.79 (-4.21%)
ORCL  145.40
-4.91 (-3.27%)
TSLA  402.51
-6.07 (-1.49%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.